New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:55 EDTGILDGilead Q1 results 'outstanding,' says Wells Fargo
After Gilead reported stronger than expected Q1 results, Wells Fargo thinks that the company's Sovaldi sales likely exceeded most Street estimates. The firm thinks the strong Sovaldi launch bodes well for the drug's long-term outlook. It keeps an $87-$91 price target and Outperform rating on the stock.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
April 10, 2015
16:05 EDTGILDOptions Update; April 10, 2015
Subscribe for More Information
April 9, 2015
06:12 EDTGILDSovaldi prices causes Medicaid spending for hepatitis C drugs to soar, WSJ says
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
April 6, 2015
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use